| Bank of America Says Buy These 3 Stocks for a Double-Digit Rally | 08/14 11:46 | investorplace.com |
| Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates | 07/30 09:40 | zacks.com |
| Day One Reports Second Quarter 2024 Financial Results and Corporate Progress | 07/30 07:30 | globenewswire.com |
| Day One Announces Oversubscribed $175.0 Million Private Placement | 07/30 07:00 | globenewswire.com |
| Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor | 07/25 00:58 | globenewswire.com |
| Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up | 06/19 11:30 | zacks.com |
| Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers | 06/18 08:30 | globenewswire.com |
| Day One Announces Sale of Priority Review Voucher for $108 Million | 05/30 08:30 | globenewswire.com |
| Day One Reports First Quarter 2024 Financial Results and Corporate Progress | 05/06 16:30 | globenewswire.com |
| Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | 04/23 15:56 | globenewswire.com |